We do not object. The only thing is that, again, we believe in a transparent system, in a way that the manufacturer, the regulatory agency, the prescribing physician, and the patient are part of a partnership of communication. The information is available and is becoming more and more available through the registries I mentioned. The off-label use that you referred to is something that we, the manufacturer, obviously cannot be responsible for. We know that sometimes doctors do that, but that's medical practice. We have a product monograph that clearly defines what indication, what is the target population, what are the risks.
If you look at the product monograph of a drug, you will see that there is a list of adverse events by frequency of event. As I mentioned, though, these are data coming from controlled clinical trials and a controlled environment. Once the drug goes on the market, we have to monitor. If the risk-benefit profile evolves in a negative manner, then there are means for Health Canada to remove the product or restrict the product in terms of usage.